Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella MMRV—Priorix-Tetra™ Compared to Separate MMR   V VaccinationReport as inadecuate




Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella MMRV—Priorix-Tetra™ Compared to Separate MMR   V Vaccination - Download this document for free, or read online. Document in PDF available to download.

Drug Safety

, Volume 38, Issue 11, pp 1095–1102

First Online: 07 August 2015

Abstract

IntroductionMeasles, mumps, rubella, and varicella combination vaccines MMRV facilitate varicella vaccination uptake compared with separate administration of measles, mumps, and rubella vaccine MMR with varicella vaccine V. However, the risk of developing febrile convulsions FC is higher in children vaccinated with MMRV.

ObjectivesThe aim was to demonstrate how to put the increased FC risk associated with MMRV into perspective by comparing it with the lower V-coverage risk associated with MMR + V.

MethodsFC and varicella burdens were measured by total numbers or duration of hospitalisations. A model, based on several assumptions and integrating parameters from heterogeneous data sources relevant to Germany, was developed to evaluate hospitalisation ratios HRs; ratios between yearly numbers of varicella-related hospitalisation days prevented by MMRV and yearly numbers of FC-related hospitalisation days attributed to MMRV, both compared with MMR + V. A sensitivity analysis estimated HR under different scenarios beyond the German experience.

ResultsFor parameter values compatible with the German experience, where MMRV Priorix-Tetra™, GSK, Belgium was introduced in 2006, the model predicted that transitioning from MMR + V to MMRV would induce 225 vaccine-related FC hospitalisation days whilst preventing 1976 varicella-related hospitalisation days per year. The HR estimated by Monte Carlo simulations was 8.5 95 % confidence interval: 1.99–25.22. A sensitivity analysis on two key parameters suggested that transitioning from MMR + V to MMRV would be favourable in situations where MMRV use would significantly impact varicella vaccination uptake.

ConclusionsMMRV use instead of MMR + V can substantially reduce the number of hospitalisation days, despite increased FC risk when MMRV is used as a first dose of measles-containing vaccine.

Download fulltext PDF



Author: Vincent Bauchau - Lionel Van Holle - Carine Cohen

Source: https://link.springer.com/







Related documents